New hope for kids with Tough-to-Treat leukemia
NCT ID NCT06054113
Summary
This study is testing a drug called blinatumomab in Chinese children whose B-cell acute lymphoblastic leukemia (B-ALL) has come back or hasn't responded to other treatments. The main goal is to see if the drug can put the cancer into remission. Researchers will also closely monitor the drug's safety and how the body processes it.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY B PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Children's Hospital of Soochow University
Suzhou, Jiangsu, 215002, China
-
Childrens Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, 400015, China
-
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, 300020, China
-
Shanghai Children's Medical Center
Shanghai, Shanghai Municipality, 200127, China
-
The Second Hospital of Anhui Medical University
Hefei, Anhui, 230601, China
-
Wuhan Childrens Hospital
Wuhan, Hubei, 430015, China
-
Zhujiang Hospital of Southern Medical University
Guangzhou, Guangdong, 510280, China
Conditions
Explore the condition pages connected to this study.